Analgetic activity of calcitonin in patients with painful osteolytic metastases of breast cancer. Results of a controlled randomized study.

Roth A, Kolarić K

Oncology1 Jan 1986Cited by 38 (Europe PMC)

PMID3531953DOI10.1159/000226383PepBankPUB-03531953

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with painful osteolytic metastases, salmon calcitonin significantly reduced analgesic consumption versus placebo.
In plain wordsIn women with painful bone metastases, salmon calcitonin significantly reduced pain medicine use versus placebo.
Peptide
Calcitonin-salmon
Outcome
DecreaseAnalgesic consumption
Study
n = 40
Comparator
Physiological solution placebo
Outcome group
Pain · Nervous system and cognition
Studied dose
100 IU daily · subcutaneous · 28 daysAs given in this study (human).
Source sentences
Summary
Statistically significant differences were established in terms of reduced analgesic consumption, shorter duration of pain and the patient's subjective assessment of pain duration and intensity; the difference was not statistically significant with regard to patient's functional capacity.
2 context sentences(design, population, supporting numbers)
Summary · context
The analgesic effect of salmon calcitonin was tested by a double-blind clinical randomized controlled trial in 40 female patients with painful osteolytic metastases.
Summary · context
Twenty patients were administered (daily) 100 IU of salmon calcitonin subcutaneously over 28 days, while the other 20 were administered identical ampoules containing 2 ml of physiological solution over the same period of time.
Report a problemFND-0353195301
02HumanRandomized controlled trialEfficacy outcome
In women with painful osteolytic metastases, salmon calcitonin significantly shortened pain duration versus placebo.
In plain wordsIn women with painful bone metastases, salmon calcitonin significantly shortened pain duration versus placebo.
Peptide
Calcitonin-salmon
Outcome
DecreasePain duration
Study
n = 40
Comparator
Physiological solution placebo
Outcome group
Pain · Nervous system and cognition
Studied dose
100 IU daily · subcutaneous · 28 daysAs given in this study (human).
Source sentences
Summary
Statistically significant differences were established in terms of reduced analgesic consumption, shorter duration of pain and the patient's subjective assessment of pain duration and intensity; the difference was not statistically significant with regard to patient's functional capacity.
2 context sentences(design, population, supporting numbers)
Summary · context
The analgesic effect of salmon calcitonin was tested by a double-blind clinical randomized controlled trial in 40 female patients with painful osteolytic metastases.
Summary · context
Twenty patients were administered (daily) 100 IU of salmon calcitonin subcutaneously over 28 days, while the other 20 were administered identical ampoules containing 2 ml of physiological solution over the same period of time.
Report a problemFND-0353195302
03HumanRandomized controlled trialEfficacy outcome
In women with painful osteolytic metastases, patients' subjective assessment of pain duration differed significantly between salmon calcitonin and placebo.
In plain wordsIn women with painful bone metastases, patients' own rating of pain duration differed significantly between salmon calcitonin and placebo.
Peptide
Calcitonin-salmon
Outcome
Direction not reportedSubjective pain duration
Study
n = 40
Comparator
Physiological solution placebo
Outcome group
Pain · Nervous system and cognition
Studied dose
100 IU daily · subcutaneous · 28 daysAs given in this study (human).
Source sentences
Summary
Statistically significant differences were established in terms of reduced analgesic consumption, shorter duration of pain and the patient's subjective assessment of pain duration and intensity; the difference was not statistically significant with regard to patient's functional capacity.
2 context sentences(design, population, supporting numbers)
Summary · context
The analgesic effect of salmon calcitonin was tested by a double-blind clinical randomized controlled trial in 40 female patients with painful osteolytic metastases.
Summary · context
Twenty patients were administered (daily) 100 IU of salmon calcitonin subcutaneously over 28 days, while the other 20 were administered identical ampoules containing 2 ml of physiological solution over the same period of time.
Report a problemFND-0353195303
04HumanRandomized controlled trialEfficacy outcome
In women with painful osteolytic metastases, patients' subjective assessment of pain intensity differed significantly between salmon calcitonin and placebo.
In plain wordsIn women with painful bone metastases, patients' own rating of pain intensity differed significantly between salmon calcitonin and placebo.
Peptide
Calcitonin-salmon
Outcome
Direction not reportedSubjective pain intensity
Study
n = 40
Comparator
Physiological solution placebo
Outcome group
Pain · Nervous system and cognition
Studied dose
100 IU daily · subcutaneous · 28 daysAs given in this study (human).
Source sentences
Summary
Statistically significant differences were established in terms of reduced analgesic consumption, shorter duration of pain and the patient's subjective assessment of pain duration and intensity; the difference was not statistically significant with regard to patient's functional capacity.
2 context sentences(design, population, supporting numbers)
Summary · context
The analgesic effect of salmon calcitonin was tested by a double-blind clinical randomized controlled trial in 40 female patients with painful osteolytic metastases.
Summary · context
Twenty patients were administered (daily) 100 IU of salmon calcitonin subcutaneously over 28 days, while the other 20 were administered identical ampoules containing 2 ml of physiological solution over the same period of time.
Report a problemFND-0353195304
05HumanRandomized controlled trialEfficacy outcome
In women with painful osteolytic metastases, functional capacity did not differ significantly between salmon calcitonin and placebo.
In plain wordsIn women with painful bone metastases, physical function did not differ significantly between salmon calcitonin and placebo.
Peptide
Calcitonin-salmon
Outcome
No significant changeFunctional capacity
Study
n = 40
Comparator
Physiological solution placebo
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
100 IU daily · subcutaneous · 28 daysAs given in this study (human).
Source sentences
Summary
Statistically significant differences were established in terms of reduced analgesic consumption, shorter duration of pain and the patient's subjective assessment of pain duration and intensity; the difference was not statistically significant with regard to patient's functional capacity.
2 context sentences(design, population, supporting numbers)
Summary · context
The analgesic effect of salmon calcitonin was tested by a double-blind clinical randomized controlled trial in 40 female patients with painful osteolytic metastases.
Summary · context
Twenty patients were administered (daily) 100 IU of salmon calcitonin subcutaneously over 28 days, while the other 20 were administered identical ampoules containing 2 ml of physiological solution over the same period of time.
Report a problemFND-0353195305
06HumanRandomized controlled trialEfficacy outcome
In women with painful osteolytic metastases, investigators rated treatment moderately useful in 11 calcitonin patients versus 3 placebo patients.
In plain wordsIn women with painful bone metastases, investigators rated treatment moderately useful in 11 calcitonin patients versus 3 placebo patients.
Peptide
Calcitonin-salmon
Outcome
IncreaseInvestigator assessment: moderately useful
Study
n = 40
Comparator
Physiological solution placebo
Outcome group
Pain · Nervous system and cognition
Studied dose
100 IU daily · subcutaneous · 28 daysAs given in this study (human).
Measurements
Moderately useful
11 patients
calcitonin
Moderately useful
3 patients
placebo
Source sentences
Summary
The objective assessment of the analgesic effect of calcitonin by the investigator showed the drug to be extremely useful in 3 patients and moderately useful in 11 patients; 3 instances of 'moderately useful' were observed in the placebo group.
2 context sentences(design, population, supporting numbers)
Summary · context
The analgesic effect of salmon calcitonin was tested by a double-blind clinical randomized controlled trial in 40 female patients with painful osteolytic metastases.
Summary · context
Twenty patients were administered (daily) 100 IU of salmon calcitonin subcutaneously over 28 days, while the other 20 were administered identical ampoules containing 2 ml of physiological solution over the same period of time.
Report a problemFND-0353195307
07HumanNon-randomized trialEfficacy outcome
In women with painful osteolytic metastases, investigators rated salmon calcitonin extremely useful in 3 patients.
In plain wordsIn women with painful bone metastases, investigators rated salmon calcitonin extremely useful in 3 patients.
Peptide
Calcitonin-salmon
Outcome
Not applicableInvestigator assessment: extremely useful
Study
n = 20
Outcome group
Pain · Nervous system and cognition
Studied dose
100 IU daily · subcutaneous · 28 daysAs given in this study (human).
Measurements
Extremely useful
3 patients
calcitonin
Source sentences
Summary
The objective assessment of the analgesic effect of calcitonin by the investigator showed the drug to be extremely useful in 3 patients and moderately useful in 11 patients; 3 instances of 'moderately useful' were observed in the placebo group.
2 context sentences(design, population, supporting numbers)
Summary · context
The analgesic effect of salmon calcitonin was tested by a double-blind clinical randomized controlled trial in 40 female patients with painful osteolytic metastases.
Summary · context
Twenty patients were administered (daily) 100 IU of salmon calcitonin subcutaneously over 28 days, while the other 20 were administered identical ampoules containing 2 ml of physiological solution over the same period of time.
Report a problemFND-0353195306
08HumanNon-randomized trialActivity measurement
In women with painful osteolytic metastases, serum calcium showed no change during the calcitonin trial.
In plain wordsIn women with painful bone metastases, blood calcium did not change during the calcitonin trial.
Peptide
Calcitonin-salmon
Outcome
No significant changeSerum calcium
Study
n: not reported in source
Outcome group
Calcium Metabolism · Endocrine and hormones
Studied dose
100 IU daily · subcutaneous · 28 daysAs given in this study (human).
Source sentences
Summary
No changes were observed in serum calcium levels; there were likewise no skeleton changes as established by X-rays and bone scintiscans before and at the end of treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
The analgesic effect of salmon calcitonin was tested by a double-blind clinical randomized controlled trial in 40 female patients with painful osteolytic metastases.
Summary · context
Twenty patients were administered (daily) 100 IU of salmon calcitonin subcutaneously over 28 days, while the other 20 were administered identical ampoules containing 2 ml of physiological solution over the same period of time.
Report a problemFND-0353195308
09HumanNon-randomized trialEfficacy outcome
In women with painful osteolytic metastases, X-rays and bone scintiscans showed no skeletal changes during the calcitonin trial.
In plain wordsIn women with painful bone metastases, X-rays and bone scans showed no bone changes during the calcitonin trial.
Peptide
Calcitonin-salmon
Outcome
No significant changeSkeletal imaging changes
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU daily · subcutaneous · 28 daysAs given in this study (human).
Source sentences
Summary
No changes were observed in serum calcium levels; there were likewise no skeleton changes as established by X-rays and bone scintiscans before and at the end of treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
The analgesic effect of salmon calcitonin was tested by a double-blind clinical randomized controlled trial in 40 female patients with painful osteolytic metastases.
Summary · context
Twenty patients were administered (daily) 100 IU of salmon calcitonin subcutaneously over 28 days, while the other 20 were administered identical ampoules containing 2 ml of physiological solution over the same period of time.
Report a problemFND-0353195309

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.